PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. - Wikidata - wikimedia - TriplyDB

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

http://www.wikidata.org/entity/Q33939881

about

Mapping biological behaviors by application of longer-lived positron emitting radionuclides Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.PET of EGFR expression with an 18F-labeled affibody molecule.Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers 86Y based PET radiopharmaceuticals: radiochemistry and biological applications PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu Intraoperative imaging in ovarian cancer: fact or fiction?A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.Multimodality molecular imaging of disease progression in living subjects.Imaging EGFR and HER2 by PET and SPECT: a review.Matching chelators to radiometals for radiopharmaceuticals.Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.Beyond the margins: real-time detection of cancer using targeted fluorophores.Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.Efficient route to pre-organized and linear polyaminopolycarboxylates: Cy-TTHA, Cy-DTPA and mono/di- reactive, tert-butyl protected TTHA/Cy-TTHA.New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice.[Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer].Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).

P2860

Q26824070-6883F3B9-2ACD-421F-9406-45372BDFCDFF Q33661325-2DACBEF1-407F-47F3-B2C0-1B57E1DD8C99 Q33851546-3542855B-780E-4465-B7C5-A98E55E3EB92 Q33862523-4CF1787B-014D-4439-8618-5F27C7BFFD1E Q33920975-48E1A5CB-3017-4BC0-8E4D-FE12804898B4 Q34126406-F76CE32E-979D-4E0B-A497-86298C04BBDF Q34429075-F49712D4-F5C6-4F76-B196-AAD6B5D1C171 Q34473719-1382F4C6-682B-4D38-B1A8-723B839A5BA6 Q35162293-D1786445-6A30-49BC-8391-ED9E3951F572 Q35250409-E554D1E4-FD14-4D32-83DB-12C63A4CDECE Q35655093-169BF89C-C1ED-4E7C-9B7D-870B08696D5C Q36213374-2F806277-E468-4A4F-AFA0-6B531A025799 Q36339722-219711B0-7A38-4226-ABFA-24B0B6BFC28F Q37142624-92707673-3791-4497-AC0E-3FC82C1E9C1E Q37149571-062F56C8-5D6A-4915-B1EE-112E4BF6C0EC Q37172093-0325CAFF-68AB-4F31-9218-13493D668428 Q37244880-08E06EB6-180D-4243-B751-E91AA013EA15 Q37389699-3CB5D463-CB09-420D-B9BE-8681429EC178 Q37689802-AF05C91D-D86B-4A12-8410-3032DF5881F6 Q37860943-07C46791-C7C6-43D9-A296-3E392C771740 Q37864159-B959231E-5219-42ED-8A39-EBA30FE5E4D3 Q37864161-6AC75CB9-4051-42F6-92C8-591FA8035FB8 Q37869905-40F0C0AB-B6F0-44B5-9A3F-1AFD90D61DDE Q37907736-E4E47842-3107-4E8B-A028-B7F7D5A10930 Q38137829-23A775B8-2A48-405C-95BA-571C899475F3 Q38156660-F6B634A2-7245-4A59-A58B-E64F11463D5B Q39018435-3F072769-20BA-453B-A81A-80FC5D0B1D61 Q39091749-75074885-49EC-48A5-9E7B-4C2C95150D56 Q39205052-D741CAC6-D4FE-49D7-89A4-8F2D22D251D9 Q39289085-529C4605-4F32-4911-B283-B687DC384FAC Q41485304-BC0F9462-D512-4E91-A6B0-902D6CAAF203 Q49613737-A83B67A8-CF9E-4B07-933D-F71816459CEC Q50467877-E004056D-FE7E-4A15-AC48-2B4CA73939B1 Q53202267-63214AC9-92F8-40BB-83B9-5ABFC8D61858 Q53265601-7A19F3CC-7F54-448E-B6BA-5C24CB138E68 Q54336425-44FBDB93-117D-4504-AA56-64DBC6BF2EA8 Q55384914-483F79F3-1B28-4ECC-A3DA-09C2FA35F960

P2860

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

http://www.wikidata.org/entity/Q33939881

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@ast

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@en

type

label

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@ast

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@en

prefLabel

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@ast

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

@en

P1433

Q33939881-E6115AB1-6993-4397-A54A-6A8C40193984

P1476

Q33939881-17F655AC-993C-43CD-93C1-E4F8AAAA558F

P2093

Q33939881-34F02A89-76D5-4F60-813C-2B25C4563AFF

Q33939881-5AFBEFC4-2D3C-4113-814B-4778385DF4E0

Q33939881-6045B78A-17CD-4110-90A2-986340C2F132

Q33939881-734E85CF-9136-408D-9E70-45DBF7958588

Q33939881-920BE673-5B7B-4F77-8494-11668E38601C

Q33939881-927D7D3B-2298-4DCD-8079-1C484B37F06E

Q33939881-D2B992E6-53B7-4EF2-8F0A-CC44DBE3738D

P2860

Q33939881-04D22B94-5973-4D2A-9D3A-5CA36B092BA3

Q33939881-0A03B16A-F2C5-4E05-B67D-C1593AD8E440

Q33939881-0BD7DA2E-824D-4650-AF32-682621E2FDF1

Q33939881-1C2C0AFE-71E0-4C5B-A11B-7C77903A7BB5

Q33939881-2072BB0F-BC5C-4FBB-AF03-60AC4E020B68

Q33939881-32019A65-F6B4-4165-B7E3-5BE5E6916DA5

Q33939881-36012702-18FB-4D61-A837-96B6D507FAA0

Q33939881-36AF11F2-5614-45B4-9487-4B571702EDA6

Q33939881-4FB5FD64-55CE-4954-B36F-1AD9F670A9CA

Q33939881-5083477E-657A-4C9F-A4A7-532F90E8758D

P2888

Q33939881-F9B4A37D-99A3-4A51-B3A3-8AE1A6303BE2

P304

Q33939881-6ABBDF76-BEEC-4C25-9F72-4C6599456079

P31

Q33939881-F7E4D81E-FAA7-42DB-9BF3-085BBD6EE03B

P356

Q33939881-1F1B9CEE-9922-4963-9E63-2E4064D71F4A

P433

Q33939881-165683D0-7435-428C-AF20-9437E468BEB3

P478

Q33939881-7747B385-F876-4ADE-AABD-891BAE6C7062

P50

Q33939881-D566E768-C7C4-4F42-9E44-0F55A038DF70

P577

Q33939881-A118EEDE-FB70-4C17-900B-546367EFF1FA

P5875

Q33939881-23A0EBF9-AA11-4C8A-AEEA-985C3C5E76C5

P698

Q33939881-3E4A53CB-4ADF-4EED-8664-122486859E54

P921

Q33939881-6286FD53-D93E-4CB1-9511-21C77C89DEE9

P932

Q33939881-CCABAC1C-E6BB-491D-B80B-A45B2ED6E8D7

P356

S00259-009-1370-Z

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab

@en

P2093

Celeste A S Regino

http://www.w3.org/2001/XMLSchema#string

Diane E Milenic

http://www.w3.org/2001/XMLSchema#string

Karen J Wong

http://www.w3.org/2001/XMLSchema#string

Kayhan Garmestani

http://www.w3.org/2001/XMLSchema#string

Kwamena E Baidoo

http://www.w3.org/2001/XMLSchema#string

Lawrence P Szajek

http://www.w3.org/2001/XMLSchema#string

Martin W Brechbiel

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging

Epidermal growth factor receptor inhibition strategies in oncology.

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines

Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Epidermal growth factor receptor targeting in cancer.

Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.

P2888

s00259-009-1370-z

P304

1368-1376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-009-1370-Z

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41429648

http://www.w3.org/2001/XMLSchema#string

P698

20155263

http://www.w3.org/2001/XMLSchema#string

P921

P932

2891840

http://www.w3.org/2001/XMLSchema#string